MedinCell to Present at the UBS Virtual CNS Day

The chief executive of the French biopharmaceutical company Medincell is to announce the creation of a new portfolio of drugs using the BEPO technology approved by the US FDA for the treatment of schizophrenia and mdc-TJK (MdC-Cwam) in the first stage of clinical trials, according to regulators. Here is the BBC. () How is it ready to launch their innovative treatments and could earn up to $105m (27m) worth of profits from the company s long-acting injectable drug scheme, and what is expected to be the next phase of its strategy? The company is preparing to take part in an effort to boost the global economy, with the launch of two new ways to develop new medicines to help patients with more severe forms of depression and the need for addictive opioids in which they are being offered to the public in Europe and Europe. These are the details of how it has reached the market for 2024, but what does it mean for its business? Why is this announcement taking place in France? And what will happen if it is possible to get funding from investors and business leaders to discuss the future of his business. The BBC has been talking about the business behind the firm, as it prepares to start the trial of one of them. It will be announced by UBS in Paris, France and France, on Monday, March 18 - and how will it be used to treat those with serious mental health problems across the world.

Source: streetinsider.com
Published on 2024-03-15

Related news

« Meet the Panelists : Aviation

Mapfre S A : presents its Strategic Plan 2024 - 2026 with an average growth forecast of 6 percent and a roe of between 10 and 11 percent - March 15 , 2024 at 09 : 35 am EDT »